0000000000306711

AUTHOR

Ilaria Roato

showing 2 related works from this author

Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients.

2011

Many ErbB2-positive cancers may show intrinsic resistance, and the frequent development of acquired resistance to ErbB-targeted agents represents a substantial clinical problem. The constitutive NF-κB activation in some HER-2/neu positive breast cancer may represent a potential cause of resistance to trastuzumab therapy. Preclinical data revealed that 4-(N-Methyl-N- nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), the tobacco-specific nitrosamine is able to enhance NF-κB DNA binding activity and theoretically to increase the resistance to trastuzumab. Two hundred and forty-eight women with pathologically confirmed, uni- or bidimensionally measurable, HER-2-positive metastatic breast cancer (MBC…

OncologyAdultMaleCancer Researchmedicine.medical_specialtySettore MED/06 - Oncologia MedicaAntineoplastic AgentsBreast NeoplasmsDrug resistanceAntibodies Monoclonal HumanizedMetastasisBreast Neoplasms MaleAntineoplastic AgentCohort StudiesBreast cancerRetrospective StudieTrastuzumabInternal medicinemedicineHumansskin and connective tissue diseasesMetastatic breast cancer; Smoking; Trastuzumab; Adult; Aged; Aged 80 and over; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antineoplastic Agents; Breast Neoplasms; Breast Neoplasms Male; Cohort Studies; Drug Resistance Neoplasm; Female; Humans; Male; Middle Aged; Retrospective Studies; Smoking; Cancer Research; OncologyneoplasmsAgedRetrospective StudiesGynecologyAged 80 and overbusiness.industrySmokingCancerAntibodies MonoclonalRetrospective cohort studyGeneral MedicineMiddle AgedTrastuzumabmedicine.diseaseMetastatic breast cancerOncologyDrug Resistance Neoplasmtrastuzumab smoking metastatic breast cancerFemalemetastatic breast cancerBreast diseaseCohort StudiebusinessBreast NeoplasmHumanmedicine.drug
researchProduct

Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases.

2011

Receptor activator of NFκB ligand (RANKL), RANK, and osteoprotegerin (OPG) represent the key regulators of bone metabolism both in normal and pathological conditions, including bone metastases. To our knowledge, no previous studies investigated and compared RANK expression in primary tumors and in bone metastases from the same patient. We retrospectively examined RANK expression by immunohistochemistry in 74 bone metastases tissues from solid tumors, mostly breast, colorectal, renal, lung, and prostate cancer. For 40 cases, tissue from the corresponding primary tumor was also analyzed. Sixty-six (89%) of the 74 bone metastases were RANK-positive and, among these, 40 (59.5%) showed more than…

medicine.medical_specialtySettore MED/06 - Oncologia MedicaPhysiologyClinical Biochemistrycolorectal cancerBone NeoplasmsBone remodelingMetastasisProstate cancerbreast cancerOsteoprotegerinInternal medicinemedicineHumansbone metastasibiologyReceptor Activator of Nuclear Factor-kappa Bbusiness.industryMedicine (all)Bone metastasisCell Biologymedicine.diseasePrimary tumorbone metastasis; breast cancer; colorectal cancerImmunohistochemistryEndocrinologyBone Neoplasms; Humans; Immunohistochemistry; Receptor Activator of Nuclear Factor-kappa B; Medicine (all); Physiology; Clinical Biochemistry; Cell BiologyRANKLCancer researchbiology.proteinImmunohistochemistrybusinessJournal of cellular physiology
researchProduct